Overview

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

Status:
Completed

Trial end date:
2018-09-06

Target enrollment:

Participant gender:

Summary

A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema - TADI Study

Phase:

Phase 4

Details

Lead Sponsor:

Hadassah Medical Organization

Collaborator:

Bayer

Treatments:

Aflibercept